Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Blood symbols : BLUE save search
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2022-08-17 (Crawled : 22:00) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: -4.41%
H: 30.05%
C: 7.79%
zynteglo blood commercial therapy
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2022-08-17 (Crawled : 22:00) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: -4.41%
H: 30.05%
C: 7.79%
zynteglo fda blood approval therapy
FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions
Published: 2022-08-17 (Crawled : 18:00) - prnewswire.com
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: -4.41%
H: 30.05%
C: 7.79%
fda blood therapy
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2022-06-10 (Crawled : 22:00) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
| Email alert
Add to watchlist
fda blood therapy
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-11-22 (Crawled : 14:30) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: 5.7%
H: 0.44%
C: -6.81%
fda blood transfusion application gene therapy therapy license cel
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
Published: 2021-09-21 (Crawled : 01:00) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: 0.0%
H: 1.56%
C: 0.11%
fda blood gene therapy therapy license gene therapies cel
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.